Manufacturer record
Life Max Cancer Laboratories: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
37 batches manufactured by Life Max Cancer Laboratories (Uttarakhand) were declared Not of Standard Quality between November 2019 and February 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
37 records linked to Life Max Cancer Laboratories in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
0Banned or prohibited
0Recalled or suspended
37Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
37
NSQ batches since 2019
14
Products affected
Assay
Most common failure
Feb 2026
Latest alert
Flagged batches per year
2019 · 12023 · 12024 · 222025 · 122026 · 1
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Bisacodyl GR Tablets IP 5MG | LMT240480Mfg 2024-04 · Exp 2026-03 | The sample does not conform to I.P.w.r.t. the test for Dissolution and AssayAssay | SDTL, AssamState lab | Feb 2026 |
| Albendazole Tablets IP 400mg | LMT240917Mfg 2024-08 · Exp 2027-01 | The sample does not conform to the IP with respect to Assay and Dissolution.Assay | DTL, JaipurState lab | Oct 2025 |
| Ascorbic Acid Tablets IP 500 mg | LMT240702Mfg 2024-06 · Exp 2026-05 | DescriptionDescription | Jammu and KashmirState lab | Aug 2025 |
| Albendazole Tablets 400 mg. | LMT241013Mfg 2024-09 · Exp 2026-08 | The sample does not conform to IP w.r.to the tests for ? Dissolution? and ?Assay?Assay | Government Analyst,SDTL, Guwahati,AssamState lab | Jul 2025 |
| Zinc Sulphate Dispersible Tablets IP 20 mg | LMT240804Mfg 2024-07 · Exp 2026-06 | Uniformity of Dispersion & DisintegrationDisintegration | RDTL, GuwahatiCDSCO lab | May 2025 |
| Losartan Potassium 50mg & Hydrochlorthiazide 12.5mg Tablets | LMT251666Mfg 2025-02 · Exp 2027-01 | Dissolution Test: The Dissolution of Losartan Potassium and Hydrochlorthiazide does not complies within the Prescribed limit of not less than Q value i.e. 70% of labelled claim as stated in I.P 2022.Dissolution | State Drugs Laboratory, PunjabState lab | Apr 2025 |
| Levetiracetam Tablets IP 500 mg | LMT241488Mfg 2024-12 · Exp 2026-11 | DissolutionDissolution | CDTL IndoreCDSCO lab | Apr 2025 |
| Albendazole Tablets IP 400 mg | LMT241100Mfg 2024-09 · Exp 2026-08 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Apr 2025 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | LMT240449Mfg 2024-04 · Exp 2026-03 | Dissolution (Calcium) and Assay of Vitamin D3Assay | RDTL, GuwahatiCDSCO lab | Mar 2025 |
| Albendazole Tablets IP 400 mg | LMT241138Mfg 2024-10 · Exp 2026-09 | "Dissolution" of AlbendazoleDissolution | RDTL GuwahatiCDSCO lab | Feb 2025 |
| Zinc Sulphate Dispersible Tablets IP 20 mg | LMT240811Mfg 2024-07 · Exp 2026-06 | Uniformity of dispersion & DisintegrationDisintegration | RDTL GuwahatiCDSCO lab | Jan 2025 |
| Losartan Tablets IP 50 mg | LMT240826Mfg 2024-07 · Exp 2026-06 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Jan 2025 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | LMT240431Mfg 2024-04 · Exp 2026-03 | Identification and Assay of Vitamin D3 and Dissolution of CalciumAssay | RDTL GuwahatiCDSCO lab | Jan 2025 |
| Zinc Sulphate Dispersible Tablets IP 20 mg | LMT240811Mfg 2024-07 · Exp 2026-06 | Uniformity of dispersion & DisintegrationDisintegration | RDTL GuwahatiCDSCO lab | Dec 2024 |
| Glimepiride Tablets I.P. 1 mg | LMT240339Mfg 2024-03 · Exp 2026-02 | Dissolution of GlimepirideDissolution | RDTL GuwahatiCDSCO lab | Dec 2024 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | LMT240346Mfg 2024-03 · Exp 2026-02 | Assay of Vitamin D3 and Dissolution for calciumAssay | RDTL GuwahatiCDSCO lab | Dec 2024 |
| Telmisartan Tablets IP 40 mg | LMT240520Mfg 2024-05 · Exp 2026-04 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Nov 2024 |
| Telmisartan Tablets I.P. 40 mg | LMT240611Mfg 2024-05 · Exp 2026-04 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Nov 2024 |
| Telmisartan Tablets IP 40 mg | LMT240536Mfg 2024-05 · Exp 2026-04 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Oct 2024 |
| Telmisartan Tablets I.P. 40 mg | LMT240611Mfg 2024-05 · Exp 2026-04 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Oct 2024 |
| Glimepiride Tablets IP 2 mg | LMT240333Mfg 2024-03 · Exp 2026-02 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Oct 2024 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | LMT240377Mfg 2024-03 · Exp 2026-02 | Dissolution of Calcium and Assay of Vitamin D3Assay | RDTL GuwahatiCDSCO lab | Oct 2024 |
| Glimepiride Tablets IP 1 mg | LMT240339Mfg 2024-03 · Exp 2026-02 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Sep 2024 |
| Glimepiride Tablets I.P. 2 mg | LMT240157Mfg 2024-02 · Exp 2026-01 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Sep 2024 |
| Calcium 500 mg and Vitamin D3 250 IU Tablets IP | LMT240025Mfg 2024-01 · Exp 2025-12 | Assay of Calcium and Vitamin D3 and Dissolution of CalciumAssay | RDTL GuwahatiCDSCO lab | Sep 2024 |
| Telmisartan Tablets IP 40 mg | LMT240528Mfg 2024-05 · Exp 2026-04 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Aug 2024 |
| Telmisartan Tablets IP 40 mg | LMT240502Mfg 2024-04 · Exp 2026-03 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Aug 2024 |
| Telmisartan Tablets IP 40 mg | LMT240502Mfg 2024-04 · Exp 2026-03 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Aug 2024 |
| Olmesartan Medoxomil Tablets IP 40 mg | LMT240387Mfg 2024-03 · Exp 2026-02 | Dissolution of Olmesartan MedoxomilDissolution | RDTL GuwahatiCDSCO lab | Aug 2024 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | LMT231058Mfg 2023-12 · Exp 2025-11 | Assay of Calcium and vitamin D3 and Dissolution of CalciumAssay | RDTL GuwahatiCDSCO lab | Aug 2024 |
| Calcium 500 mg. with Vitamin D3 250 IU Tablets IP | LMT240412Mfg 2024-04 · Exp 2026-03 | Dissolution (Calcium) and Assay of Vitamin D3Assay | RDTL GuwahatiCDSCO lab | Jul 2024 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | LMT240376Mfg 2024-03 · Exp 2026-02 | Dissolution of Calcium & Assay of Vitamin D3Assay | RDTL GuwahatiCDSCO lab | Jul 2024 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | LMT240335Mfg 2024-03 · Exp 2026-02 | Dissolution (Calcium) and Assay of Vitamin D3Assay | RDTL GuwahatiCDSCO lab | Jul 2024 |
| Calcium 500 mg and Vitamin D3 250 IU Tablets IP | LMT240348Mfg 2024-03 · Exp 2026-02 | Dissolution of Calcium and Assay of vitamin D3Assay | RDTL GuwahatiCDSCO lab | Jul 2024 |
| Calcium 500 mg withVitaminD3250 IU Tablets IP | LMT240 263Mfg 2023-03 · Exp 2026-02 | The sample Does not Complies conforms to I.P. with respect to the above tests only.Other | RDTL GuwahatiCDSCO lab | May 2024 |
| Zinc Sulphate Tablets 50 mg Zincload-50 | LMT210773Mfg 2021-08 · Exp 2023-07 | DisintegrationDisintegration | RDTL GuwahatiState lab | Jan 2023 |
| Levocetirizine Dihydrochloride Tablets I.P. 5mg. | LC18004Mfg 2018-04 · Exp 2020-03 | DissolutionDissolution | RDTL GuwahatiState lab | Nov 2019 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.